Development of a breakthrough vaccine researchers say could eradicate breast cancer by 2030 wrapped up phase one of its clinical trial this week, with more than 75% of women showing a strong immune ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

University of Cambridge-led trial shows significant improvement in outcomes for inherited, aggressive forms of breast cancerA ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

Artificial intelligence (AI) technologies and machine learning (ML) algorithms are witnessing tremendous growth in immunology ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Explore how nanomedicine and targeted therapies are shaping the future of cancer care in BCC Research’s global market analysis of nanotechnology in oncology.”Boston, June 05, 2025 (GLOBE NEWSWIRE) -- ...

Raised over $12 million, thanks to the collective efforts of charitable partners, corporate sponsors, all 32 NHL Clubs and ...